Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Rises By 38.0%

Tharimmune, Inc. (NASDAQ:THARGet Free Report) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 36,300 shares, a growth of 38.0% from the February 13th total of 26,300 shares. Based on an average daily volume of 98,300 shares, the short-interest ratio is presently 0.4 days. Currently, 1.9% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC purchased a new position in Tharimmune, Inc. (NASDAQ:THARFree Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune at the end of the most recent quarter. Institutional investors own 1.16% of the company’s stock.

Tharimmune Stock Performance

Tharimmune stock traded up $0.02 during trading hours on Tuesday, reaching $1.43. The stock had a trading volume of 426 shares, compared to its average volume of 348,716. The business’s 50 day moving average price is $1.83 and its 200-day moving average price is $2.18. Tharimmune has a 52 week low of $1.28 and a 52 week high of $7.46.

Analyst Ratings Changes

Several equities analysts recently issued reports on THAR shares. Rodman & Renshaw started coverage on shares of Tharimmune in a report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective on the stock. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.

Check Out Our Latest Analysis on Tharimmune

Tharimmune Company Profile

(Get Free Report)

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).

Featured Stories

Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.